Stock Research for XXII

XXII

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

XXII Stock Chart & Research Data

The XXII chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the XXII chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


XXII Due diligence Resources & Stock Charts

The XXII stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View XXII Detailed Price Forecast - CNN Money CNN View XXII Detailed Summary - Google Finance
Yahoo View XXII Detailed Summary - Yahoo! Finance Zacks View XXII Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View XXII Trends & Analysis - Trade-Ideas Barrons View XXII Major Holders - Barrons
NASDAQ View XXII Call Transcripts - NASDAQ Seeking View XXII Breaking News & Analysis - Seeking Alpha
Spotlight View XXII Annual Report - CompanySpotlight.com OTC Report View XXII OTC Short Report - OTCShortReport.com
TradeKing View XXII Fundamentals - TradeKing Charts View XXII SEC Filings - Bar Chart
WSJ View Historical Prices for XXII - The WSJ Morningstar View Performance/Total Return for XXII - Morningstar
MarketWatch View the Analyst Estimates for XXII - MarketWatch CNBC View the Earnings History for XXII - CNBC
StockMarketWatch View the XXII Earnings - StockMarketWatch MacroAxis View XXII Buy or Sell Recommendations - MacroAxis
Bullish View the XXII Bullish Patterns - American Bulls Short Pains View XXII Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View XXII Stock Mentions - StockTwits PennyStocks View XXII Stock Mentions - PennyStockTweets
Twitter View XXII Stock Mentions - Twitter Invest Hub View XXII Investment Forum News - Investor Hub
Yahoo View XXII Stock Mentions - Yahoo! Message Board Seeking Alpha View XXII Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for XXII - SECform4.com Insider Cow View Insider Transactions for XXII - Insider Cow
CNBC View XXII Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for XXII - OTC Markets
Yahoo View Insider Transactions for XXII - Yahoo! Finance NASDAQ View Institutional Holdings for XXII - NASDAQ


Stock Charts

FinViz View XXII Stock Insight & Charts - FinViz.com StockCharts View XXII Investment Charts - StockCharts.com
BarChart View XXII Stock Overview & Charts - BarChart Trading View View XXII User Generated Charts - Trading View




Latest Financial News for XXII


Does The 22nd Century Group, Inc. (NYSEMKT:XXII) Share Price Fall With The Market?
Posted on Monday March 23, 2020

Anyone researching 22nd Century Group, Inc. (NYSEMKT:XXII) might want to consider the historical volatility of the...


22nd Century Group, Inc. Files 2019 Annual Report
Posted on Thursday March 12, 2020

22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced nicotine tobacco and hemp/cannabis plant genetics research and development, yesterday filed its Annual Report on Form 10-K for the year ended December 31, 2019. A supplemental letter from Michael Zercher, President and Chief Operating Officer to shareholders is available in the Investor section of the Company’s website.


22nd Century Announces Important New Achievements with KeyGene
Posted on Wednesday March 11, 2020

WILLIAMSVILLE, N.Y. , March 11, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced nicotine tobacco and hemp/cannabis plant genetics research, announced today that lead scientists from 22nd Century Group and KeyGene have assembled a high quality genome sequence of two hemp/cannabis lines and established a new, proprietary hemp/cannabis bioinformatics platform. Both are believed to be among the highest quality, hemp/cannabis reference genomes in the world. “These exciting, new developments are already enabling the rapid breeding of new and proprietary hemp/cannabis plant lines with truly remarkable and potentially novel medicinal cannabinoid profiles,” said Michael Zercher, President & Chief Operating Officer of 22nd Century Group.


22nd Century Group Adds to Leadership Team
Posted on Tuesday March 10, 2020

WILLIAMSVILLE, N.Y., March 10, 2020 -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.